期刊文献+

老年急性髓系白血病患者预后的影响因素分析

Analysis of Factors Influencing Prognosis of Elderly Patients with Acute Myeloid Leukemia
下载PDF
导出
摘要 目的分析老年急性髓系白血病患者预后的影响因素。方法对苏州大学附属张家港医院(张家港市第一人民医院)2013年1月至2017年12月收治的92例老年急性髓系白血病患者的临床资料进行回顾调查,分析影响患者预后的危险因素。结果本研究92例患者中,完全缓解26例(28.3%),中位生存期221 d;未缓解66例(71.7%),中位生存期102 d。影响因素分析显示,年龄≤70岁、功能状态评分(PS评分)<2分、初治时的白细胞计数≤50×10^9/L、接受标准化疗、白细胞CD34表达阴性、染色体低危核型的患者完全缓解率升高、中位生存期延长(P<0.05)。结论影响老年急性髓系白血病患者预后的危险因素为年龄、功能状态评分、初治时的白细胞计数、治疗方案及染色体核型。 Objective To analyze the influencing factors of prognosis in elderly patients with acute myeloid leukemia.Methods The clinical data of 92 elderly patients with acute myeloid leukemia admitted to Zhangjiagang Hospital Affiliated to Suzhou University(First People's Hospital of Zhangjiagang City)from January 2013 to December 2017 were retrospectively analyzed to analyze the risk factors affecting the prognosis of patients.Results Of the 92 patients in the study,26(28.3%)had complete remission,with a median survival of 221 days;66 patients(71.7%)had no remission,with a median survival of 102 days.Analysis of influencing factors showed that patients with age≤70 years,PS score<2 points,white blood cell count≤50×10^9/L at initial treatment,standard chemotherapy,white blood cell CD34 expression negative,chromosome low-risk karyotype patients had increased complete remission rate and prolonged median survival time(P<0.05).Conclusion The risk factors for prognosis in elderly patients with acute myeloid leukemia are age,functional status score,white blood cell count at initial treatment,treatment regimen,and karyotype.
作者 吴晓 张秋蓉 陆婷婷 黄琨 WU Xiao;ZHANG Qiurong;LU Tingting;HUANG Kun(Zhangjiagang Hospital Affiliated to Suzhou University(First People's Hospital of Zhangjiagang City),Suzhou Jiangsu 215600,China)
出处 《大医生》 2019年第16期54-55,共2页 Doctor
关键词 老年急性髓系白血病 预后 影响因素 elderly acute myeloid leukemia prognosis influencing factors
  • 相关文献

参考文献4

二级参考文献38

  • 1周凡,刘丽梅,刘彦琴,朴瑛,刘景华,郭步云.MA和DA方案治疗急性髓系白血病临床分析[J].沈阳部队医药,2005,18(5):332-333. 被引量:1
  • 2刘文,李峰敏,郭媛媛,宋辉,黄淑贤,左继爽.CAG方案治疗难治、复发性急性髓系白血病的临床疗效[J].中国煤炭工业医学杂志,2006,9(4):362-363. 被引量:5
  • 3张之南,沈悌.血液病诊断与疗效标准.第3版.北京:科学出版社,2008:99 -163.
  • 4Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study.Leukemia,1995;9(1):10-14.
  • 5Saito K,Nakamura Y.Lowdose cytarabine and aclarubicin in combination with granulocyte colony stimulating factor(CAG regimen)for previously treated patients with relapsed or primary resistant acute myelogenous leukemia(AML)and previously anemia with excess blasts in transformation.Int J Hematol,2000;71:238.
  • 6Vogelstein B,Fearon ER,Hamilton SR,et al.Genetic alterations during colorectatum or development.N Engl J Med,1988;319(9):525-532.
  • 7Momparler RL,Bovenzi V.DNA methylation and cancer.J Cell Physiol,2000;183(2):145-154.
  • 8Esteller M.Dormant hypermethylated tumour suppressor genes:questions and answers.J Pathol,2005;205(2):172-180.
  • 9Das PM,Singal R.DNA methylation and cancer.J Clin Oncol,2004;22(22):4632-4642.
  • 10Teensma DP,Stone RM.Practical recommendation for hypomethylating agent therapy of patients with myelodysplastic syndrome.Hematol Oncol Clin North AM,2010;24(6);389-406.

共引文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部